NasdaqGM:GPCRPharmaceuticals
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal
Structure Therapeutics (GPCR) has been in focus after encouraging Phase 2 results for its lead obesity drug candidate, aleniglipron, as well as a new licensing deal with Genentech covering patents tied to CT-996.
See our latest analysis for Structure Therapeutics.
Those aleniglipron Phase 2 results and the Genentech licensing deal have arrived after a strong run, with a 90 day share price return of 127.71% and a 1 year total shareholder return of 172.69%, suggesting momentum has recently been...